Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 38.92 Million USD | -4.84% |
| 2021 | 40.9 Million USD | 71.89% |
| 2020 | 23.79 Million USD | -2.19% |
| 2019 | 24.33 Million USD | 359.34% |
| 2018 | 5.29 Million USD | -64.79% |
| 2017 | 15.04 Million USD | 71.67% |
| 2016 | 8.76 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 37.31 Million USD | -4.14% |
| 2023 Q3 | 30.13 Million USD | 40.86% |
| 2023 Q2 | 21.39 Million USD | -42.66% |
| 2022 FY | 38.92 Million USD | -4.84% |
| 2022 Q3 | 47.94 Million USD | 7.45% |
| 2022 Q4 | 38.92 Million USD | -18.81% |
| 2022 Q1 | 44.22 Million USD | 8.12% |
| 2022 Q2 | 44.61 Million USD | 0.89% |
| 2021 Q2 | 24.87 Million USD | -4.78% |
| 2021 FY | 40.9 Million USD | 71.89% |
| 2021 Q3 | 30.24 Million USD | 21.57% |
| 2021 Q4 | 40.9 Million USD | 35.27% |
| 2021 Q1 | 26.12 Million USD | 9.77% |
| 2020 Q4 | 23.79 Million USD | 1.68% |
| 2020 Q3 | 23.4 Million USD | -3.25% |
| 2020 Q2 | 24.18 Million USD | -0.8% |
| 2020 Q1 | 24.38 Million USD | 0.22% |
| 2020 FY | 23.79 Million USD | -2.19% |
| 2019 FY | 24.33 Million USD | 359.34% |
| 2019 Q4 | 24.33 Million USD | -4.92% |
| 2019 Q3 | 25.59 Million USD | 410.57% |
| 2019 Q2 | 5.01 Million USD | 10.37% |
| 2019 Q1 | 4.54 Million USD | -14.27% |
| 2018 Q2 | 13.91 Million USD | -26.0% |
| 2018 FY | 5.29 Million USD | -64.79% |
| 2018 Q4 | 5.29 Million USD | -26.46% |
| 2018 Q3 | 7.2 Million USD | -48.23% |
| 2018 Q1 | 18.8 Million USD | 25.0% |
| 2017 Q4 | 15.04 Million USD | 0.0% |
| 2017 FY | 15.04 Million USD | 71.67% |
| 2016 FY | 8.76 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -706.783% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1538.342% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 70.651% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1300.756% |
| Better Therapeutics, Inc. | 23.84 Million USD | -63.271% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -369.906% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -290.277% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -47.792% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -22.477% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 43.936% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -389.92% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 19.089% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 75.257% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -1010.311% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -82.843% |
| Molecular Templates, Inc. | 31.17 Million USD | -24.882% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -211.045% |
| NexImmune, Inc. | 5.08 Million USD | -665.642% |
| Orgenesis Inc. | 35.53 Million USD | -9.546% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -135.75% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -14511.469% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1595.92% |
| Scopus BioPharma Inc. | 7.45 Million USD | -422.199% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 92.128% |
| Statera Biopharma, Inc. | 22.67 Million USD | -71.663% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -256.67% |
| Trevena, Inc. | 48.26 Million USD | 19.342% |
| Vaxxinity, Inc. | 30.94 Million USD | -25.798% |
| Vaccinex, Inc. | 5.94 Million USD | -555.116% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1877.659% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -1.444% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1309.603% |